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Abstract
Background
Germline pathogenic variants in BRCA1 and BRCA2 (BRCA) are the main cause of Heredi-
tary Breast and Ovarian Cancer syndrome (HBOC).
Methods
In this study we evaluated the mutational profile and prevalence of BRCA pathogenic/likely
pathogenic variants among probands fulfilling the NCCN HBOC testing criteria. We charac-
terized the clinical profile of these individuals and explored the performance of international
testing criteria.
Results
A pathogenic/likely pathogenic variant was detected in 19.1% of 418 probands, including
seven novel frameshift variants. Variants of uncertain significance were found in 5.7% of
individuals. We evaluated 50 testing criteria and mutation probability algorithms. There was
a significant odds-ratio (OR) for mutation prediction (p 0.05) for 25 criteria; 14 of these
had p 0.001. Using a cutoff point of four criteria, the sensitivity is 83.8%, and the specificity
is 53.5% for being a carrier. The prevalence of pathogenic/likely pathogenic variants for
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each criterion ranged from 22.1% to 55.6%, and criteria with the highest ORs were those
related to triple-negative breast cancer or ovarian cancer.
Conclusions
This is the largest study of comprehensive BRCA testing among Brazilians to date, and the
first to analyze clinical criteria for genetic testing. Several criteria that are not included in the
NCCN achieved a higher predictive value. Identification of the most informative criteria for
each population will assist in the development of a rational approach to genetic testing, and
will enable the prioritization of high-risk individuals as a first step towards offering testing in
low-income countries.
Introduction
Breast cancer is the most prevalent cancer among women, with about 5–10% of all cases
caused by inherited germline pathogenic variants in cancer predisposition genes [1]. BRCA1
and BRCA2 (collectively named BRCA hereafter) are the main genes causing hereditary breast
and ovarian cancer syndrome (HBOC), and are also associated with an increased risk of pros-
tate and pancreatic cancers [2]. Pathogenic variants in the BRCA genes are the most powerful
predictors of developing breast and ovarian cancer, with a 40–80% lifetime risk of developing
breast cancer, and 11–50% of developing ovarian cancer, respectively [3]. HBOC patients may
benefit from risk-reducing surgery (mastectomy and salpingo-oophorectomy), chemopreven-
tion and enhanced surveillance approaches [4], therefore identification of carriers is crucial for
cancer prevention and control. Thus, genetic cancer risk assessment (GCRA) and genetic test-
ing should be an option for patients whose personal and/or family history is suggestive of
HBOC syndrome [5].
Brazilian individuals with suspected HBOC syndrome have limited access to GCRA and
genetic testing, which has only become available recently for patients with private health insur-
ance. The majority (about 70%) of the population relies on the public health care system,
wherein genetic counseling is only available in a few reference centers and genetic testing is
not offered [6]. In addition, only a few studies reported on comprehensive BRCA variant
screening [7–10]. Finally, while international criteria (i.e. NCCN-based), have been routinely
used to identify candidates for genetic testing in Brazil, there has been no assessment of the
performance of these criteria in this specific population.
Although there are similarities among BRCA testing criteria worldwide, there is no consen-
sus and it is reasonable to hypothesize that the prevalence of pathogenic variants will differ
according to the population being studied and the testing criteria used [11]. The purpose of
this study was to evaluate the prevalence of BRCA1 and BRCA2 pathogenic/likely pathogenic
variants and clinical profiles of individuals fulfilling the NCCN HBOC testing criteria in
Southern Brazil with the aim of assessing the performance of these and other widely used
international testing criteria in this specific population.
Materials and methods
Subjects and ethical aspects
Study subjects were recruited in the city of Porto Alegre, Southern Brazil, from cancer genetics
clinics in Hospital de Clı´nicas de Porto Alegre (a public general hospital) and private health
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care offices. All participants were unrelated and had to fulfill BRCA testing criteria according
to the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2014) for
inclusion in the study. The fulfillment of NCCN HBOC criteria was assessed through indepen-
dent review of all pedigrees by at least two of the authors. This project was approved by the
Institutional Review Board from the Hospital de Clı´nicas de Porto Alegre and all individuals
provided written or verbal consent for BRCA testing and all participants received pre- and
post-test genetic counseling. Since our sequencing data contain sensitive patient information,
and patients did not consent to full disclosure of all sequencing information, we have some
ethical limitations regarding the raw data access. Specific data requests can, however, be ana-
lyzed in a case-by-case basis, and might be available upon request.
Clinical data and pedigrees
The family history of each participant was recorded, including first-, second- and third-degree
relatives on both the maternal and paternal sides of the family, and spanning at least three gen-
erations. Confirmation of the personal and family history of cancer was attempted in all cases,
through pathology and medical reports as well as death certificates. Clinical data (gender,
birthplace, age at cancer diagnosis, tumor type, immunohistochemistry and histology data)
were obtained from a review of medical records. For cases in which the age at diagnosis was
unavailable, it was conservatively estimated to be older than 60 years. Both lineages were
assessed and all pedigrees were evaluated in a single lineage (maternal or paternal), unless
there was explicit information on patient adoption. Otherwise, unless specified by the guide-
line, pedigrees were restricted to three generations. Fallopian tube and primary peritoneal can-
cers were included as ovarian cancers, and both invasive and in situ breast carcinomas were
included.
Geographic distribution of proband’s birthplaces were analyzed in R using the packages
maptools and maps, version 3.2.3 (https://www.R-project.org/) [12], along with geographic
coordinates obtained from Google Maps (google.com.br/maps).
Genetic testing
Whenever possible, the initial testing was carried out in a family member with breast or ovar-
ian cancer (affected individuals). However, in some families, only an unaffected individual (or
an individual with a diagnosis other than breast and/or ovarian cancer) was available for test-
ing. Sequencing analysis of the entire coding region of the BRCA1 and BRCA2 genes and
intron-exon junctions was performed in all cases, either using next generation sequencing
(NGS) or Sanger sequencing. Probands tested at Hospital de Clı´nicas de Porto Alegre (HCPA)
were sequenced either by Sanger dye terminator sequencing or NGS on the Ion Torrent Per-
sonal Genome Machine (PGM) platform. Sequencing on the PGM was carried out according
to the manufacturer’s instructions using the Ion AmpliSeq BRCA1 and BRCA2 Community
Panel and Ion AmpliSeq Library kit 2.0. All VUS or likely pathogenic/pathogenic variants
identified by NGS in these patients were confirmed by Sanger sequencing. Large genomic rear-
rangement testing (LGR) of both BRCA1 and BRCA2 was done in the majority of probands.
All probands tested at HCPA, and those tested in commercial laboratories with Sanger se-
quencing were evaluated by Multiplex Ligation-Dependent probe Amplification (MLPA), car-
ried out using MRC-Holland commercial kits for BRCA1 (SALSA MLPA P002-D1) and
BRCA2 (SALSA MLPA P045-B3) according to the manufacturer’s instructions. Multiplex PCR
amplified products were separated by capillary gel electrophoresis in an ABI 3500 Genetic
Analyzer. Information on copy number was analyzed with Coffalyser Software (MRC-Hol-
land, http://www.mrc-holland.com/). Identified rearrangements were confirmed in an
BRCA1 and BRCA2 mutational profile and testing criteria in Southern Brazil
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additional independent experiment, performed with confirmatory kits using different probes:
SALSA MLPA P087 for BRCA1 and SALSA MLPA P077 for BRCA2. Probands recruited from
private genetic counseling clinics which had genetic testing done by NGS were all tested also
by MLPA if the NGS platform did not allow LGR detection. In cases tested with a NGS work-
flow that allowed the detection of LGR, all identified LGR were confirmed by MLPA. BRCA
sequencing results (single nucleotide variants and small insertions and deletions only, not
including any clinical data or clinical comparisons) of 193 cases were previous published [13].
In silico analyses
In order to estimate the impact of variants of uncertain significance on protein structure, func-
tion and evolutionary conservation, we used three different predictors: PredictSNP [14],
which combines the results of six prediction tools (MAPP, PhD-SNP, Poly-Phen1, Poly-
Phen2, SIFT), AlignGVGD, [15] and MutationTaster [16].
Variants were named following Human Genome Variation Society (HGVS) nomenclature
guidelines. The biological significance of all variants were assessed using the databases: CLIN-
VAR (https://www.ncbi.nlm.nih.gov/clinvar), BRCA Share (formerly known as UMD; http://
www.umd.be), LOVD (http://databases.lovd.nl/shared/genes), ARUP (http://arup.utah.edu/
database/BRCA) and BRCA Exchange (http://brcaexchange.org). Novel variants were classi-
fied according to the ACMG [17] guidelines. The population databases 1000 Genomes [18]
(http://www.internationalgenome.org/), ExAC [19] (http://exac.broadinstitute.org/), FLOS-
SIES (https://whi.color.com) and AmbryShare (https://share.ambrygen.com) were consulted
to evaluate the population frequency of variants of uncertain significance with full knowledge
that the Brazilian population is vastly underrepresented in these databases. All likely patho-
genic variants were considered with pathogenic variants (and collectively named “pathogenic
variants” hereafter) for analysis of selection criteria, as is standard practice in GCRA.
Testing criteria
Pedigrees were evaluated for the fulfilment of several different BRCA testing criteria, including
National Comprehensive Cancer Network (NCCN)[20] criteria, the American Society of Clin-
ical Oncology (ASCO) [21, 22], American Society of Breast Surgeons (ASBS) [23], Society of
Gynecologic Oncology (SGO) [24], Spanish Society of Medical Oncology (SEOM) [25], The
Institute of Cancer Research (ICR; NHS Foundation Trust) [26] and the Brazilian National
Supplementary Health Insurance Agency (ANS) [27], which uses NCCN-based testing criteria
and provides access to genetic testing for patients with private health insurance only. As some
of the guidelines have overlapping criteria, in total we analyzed 50 distinct criteria. We used
additional tools to assess predicted pathogenic variant prevalence or empiric prior probabili-
ties of carriage of pathogenic variants, such as the Manchester [28] and PennII [29] models
and the Myriad Mutation Prevalence Tables [30]. To dichotomize the values provided by these
models, we set 10% as a minimum probability of being a carrier as a determinant criteria to
offer genetic testing, based on the widely accepted ASCO guidelines [21]. All testing criteria,
references and specifications are summarized in S1 Table.
Statistical analysis
Fisher’s exact test was used to determine if there was a significant association between the pres-
ence of a pathogenic variant and clinical and pathologic features. Logistic regression was used
to determine the odds ratios (ORs) and 95% confidence intervals (CIs). The OR value was
used to evaluate the association of each criteria with carrier status.
BRCA1 and BRCA2 mutational profile and testing criteria in Southern Brazil
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Receiver operating characteristic (ROC) curves and area under the curve (AUC) was used
to determine how many criteria should be fulfilled to predict mutation, and we used 3 different
criteria sets: 1) considering all evaluated criteria; 2) only criteria with p 0.05 on OR analysis;
and 3) only criteria with p 0.001 on the same analysis. The cut point was chosen to reach
maximum sensitivity and specificity, considering the value of sensitivity > 70%.
The Mann–Whitney test was used to evaluate the difference between ages at diagnosis. All
statistical tests were 2-sided. All analyses were performed using Statistical Product and Service
Solutions (SPSS) software version 18.0 (IBM).
Results
Clinical features of the cohort
A total of 418 unrelated probands were enrolled in this study. All participants were recruited
in Porto Alegre, the southernmost capital of Brazil. As depicted in Fig 1, 94.6% of individuals
were born in the Southern region of Brazil. Eight probands had non-Brazilian nationalities
including: Uruguay (3), the Republic of Armenia, Colombia, China, Russia and Romania (1
each). Most individuals were breast cancer (BC) affected women (N = 330, 79%), while only 37
(8.8%) had been diagnosed with ovarian cancer (OC). Fifty-four (13%) individuals were not
affected by cancer, but fulfilled NCCN testing criteria. The mean age at diagnosis was 41.6
(standard deviation, SD = 10.5) years for BC and 45.3 (SD = 13.9) years for OC patients.
Among patients with bilateral BC (14 synchronous and 27 metachronous primaries), the mean
age at diagnosis was 43.1 (SD = 11.4) and 49.0 (SD = 13.3) years for the first and second
tumors, respectively. The characterization of tumor types, ethnicity, BC receptor status, BC
and OC histology and age at diagnosis are summarized in Table 1.
Pathogenic variants identified in BRCA1 and BRCA2
Almost half of all BRCA testing was performed in Brazil (48.8%), with the remaining tests per-
formed in the United States of America (50.5%), Canada, Spain, and Switzerland (collectively
0.7%). For BRCA sequencing, NGS was the method of choice to sequence 88.3% (369/418) of
all patients, and the entire coding region of both genes was covered for all probands (data not
shown).
Eighty-three pathogenic variants in the BRCA1 and/or BRCA2 genes were identified in 80
of the 418 probands (19.1%). When only cancer affected probands are considered the preva-
lence of pathogenic variants rises to 20%, while among cancer unaffected probands with a suspi-
cious family history (i.e. a family history characterized by the presence of specific cancer types
and ages, leading to the suspicion of hereditary breast and ovarian cancer syndrome, according
to HBOC-NCCN criteria), the prevalence was close to 13%. Among breast and ovarian cancer
patients the detection rate of pathogenic variants was 19.7% and 37.8%, respectively.
Fig 2 depicts the 83 pathogenic variants identified in this cohort, corresponding to 56
unique pathogenic variants carried by 80 probands. In BRCA1, four distinct LGR and 28 dif-
ferent pathogenic SNVs and small insertions and deletions (indels) were identified in 51 pro-
bands, representing 61.4% of all pathogenic variants found in the study. In BRCA2, only one
LGR was identified (the Portuguese founder pathogenic variant c.156_157insAluYa5) and 23
distinct pathogenic SNV/indels were found in 31 probands. Of interest, two double heterozy-
gotes (DH), carrying one BRCA1 and one BRCA2 pathogenic variant were identified. The first
patient was heterozygous for BRCA1 c.4357+1G>T and BRCA2 c.6405_6409delCTTAA, while
the second patient was heterozygous for a BRCA1 LGR (deletion of exons 4–6) and BRCA2
c.9004G>A. In addition, we identified a patient carrying two heterozygous BRCA2 pathogenic
variants (c.8878C>T and c.9699_9702delTATG). All pathogenic variants identified, along
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with their predicted protein sequences and associated personal history of cancer are described
in S2 Table.
Complete BRCA1 and BRCA2 LGR analysis was done for 340 (81.3%) probands, and a total of
336 (98.8%) individuals had a wild type result. Forty-eight probands with a pathogenic variant
detected by sequencing, and 19 probands with a wild type (WT) sequencing result chose not to
proceed with LGR testing. In 11 probands, LGR testing was incomplete, including only BRCA1 or
five specific BRCA1 rearrangements (3.8 kb deletion in exon 13, 510 kb deletion in exon 22, 7.1 kb
deletion in exons 8–9, 26 kb deletion in exons 14–20, and a 6 kb insertion in exon 13).
In eight probands, seven unique novel frameshift variants were identified: c.2250dupC
(p.Met751Hisfs), c.2910dupA (p.His971Thrfs), c.4663delA (p.Arg1555Glyfs) and c.4736_
4739delCTTC (p.Pro1579Leufs) in BRCA1; and c.2505dupA (p.Pro836Thrfs), c.7580_
7583dupTAGG (p.Gly2529Argfs, in two probands) and c.9282_9397del (p.Asp3095Argfs) in
BRCA2. These variants were not previously described in the literature nor are they present in
the ClinVar, BRCAShare, ARUP/BRCA, KConFab, LOVD and BRCA Exchange databases.
Considering all available evidence and the ACMG[17] guidelines, all novel variants were classi-
fied as likely pathogenic.
Clinical features in carriers of pathogenic variants and non-carriers
We compared clinical features between probands with and without pathogenic variants. As
described in Table 1, there were no statistically significant differences between these two
Fig 1. Geographic distribution of probands included in this study in the southern region of Brazil. The size of the dots corresponds to the
number of probands from each location. The purple triangle represents the State’s capital, Porto Alegre, from which 140 probands derive. RS, Rio
Grande do Sul; SC, Santa Catarina; PR, Parana´.
https://doi.org/10.1371/journal.pone.0187630.g001
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Table 1. Clinical and pathologic features in BRCA1 and BRCA2 carriers of pathogenic variants and
non-carriers.
All
participants
(N = 418)
Carriers of
pathogenic
variants
(N = 80)
Non-
carriers*
(N = 338)
P-value
N % N % N % Carriers vs Non-carriers
Gender
Female 408 97.6 78 97.5 330 97.6 1.00
Male 10 2.4 2 2.5 8 2.4
Birthplacea
Brazil 365 97.9 70 98.6 295 97.7 0.419
Southern Brazil 353 94.6 66 93.0 287 95.0
Others 12 3.2 4 5.6 8 2.6
Other countries 8 2.1 1 1.4 7 2.
Cancer affected
Breast cancer only 319 76.3 59 73.8 260 76.9 0.030
Single tumor 255 61.0 45 56.3 210 62.1
Bilateral 41 9.8 11 13.8 30 8.9
Ipsilateral 17 4.1 2 2.5 15 4.4
Male 6 1.4 1 1.2 5 1.5
Ovarian cancer only 26 6.2 8 10.0 18 5.3
Breast and ovarian
cancer
11 2.6 6 7.5 5 1.5
Otherb 8 1.9 0 0.0 8 2.4
Cancer unnaffected 54 13.0 7 8.7 47 13.9
Ashkenazi Jewish ethnicity
Yes 13 3.1 5 6.3 8 2.4 0.082
No 405 96.9 75 93.7 330 97.6
Breast cancer receptor
statusc
TNBC 78 29.8 34 59.7 44 21.5 <0.0001
HR-positive/
HER2-negative
139 53.0 20 35.0 119 58.0
HR-negative/
HER2-positive
17 6.5 3 5.3 14 6.8
HR-positive/
HER2-positive
28 10.7 0 0 28 13.7
Histology of breast cancerd
IDC 210 72.4 48 87.3 162 68.9 0.047
DCIS 19 6.6 0 0.0 19 8.0
ILC 19 6.6 1 1.8 18 7.7
LCIS 3 1.0 0 0.0 3 1.3
IDC + ILC 6 2.0 0 0.0 6 2.6
Other 33 11.4 6 10.9 27 11.5
Histology of ovarian cancer
Serous 10 38.5 6 75.0 4 22.2 0.026
Non-serous 16 61.5 2 25.0 14 77.8
Age at diagnosis (years)e Mean (SD) Mean (SD) Mean (SD)
Breast cancer 41.6 (10.5) 39.7 (10.3) 42.1 (10.5)
Single tumor 40.8 (9.8) 40.3 (10.2) 40.9 (9.7)
Bilateralf 43.1 (11.4) 35.3 (8.8) 46.0 (11.0)
Ipsilateralf 43.6 (12.2) 38.5 (0.7) 44.3 (12.9)
(Continued )
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groups with regards to gender, birthplace and ethnicity. Regarding tumor type, carriers were
more frequently affected by both breast and ovarian cancer than non-carriers (p = 0.03). As
expected, triple negative breast cancer was more common in carriers, while triple positive tumors
were more common in non-carriers (p< 0.0001). The proportion of different breast cancer sub-
types was different between groups, with invasive ductal carcinoma (IDC) more common in car-
riers when compared to non-carriers. Finally, serous ovarian cancers were also more common
among carriers, while most non-carriers had other ovarian cancer histologies (p = 0.026).
Variants of uncertain significance (VUS) identified
Variants of uncertain significance were found in 24 of the 418 probands included in this study
(5.7%), including 5 distinct VUS in BRCA1, and 18 in BRCA2 (Table 2). Most were missense
variants (73.9%), followed by intronic (17.4%) and synonymous variants (8.7%). Three BRCA2
VUS (c.1680T>C, c.6271A>G and c.9502-45G>T) were novel and another three (c.2183A>
C, c.7007+53G>A and c.9502-40T>A, also in BRCA2) were described only in BRCA Ex-
change, but without any classification. The latter three VUS were present in at least one popu-
lation database at very low frequencies (< 0.0002). None of the VUS identified have been
described in the FLOSSIES database (composed of ~10,000 women older than age 70 years
who have never had cancer), AmbryShare, or ARUP/BRCA databases. None of the VUS were
co-occurring with pathogenic variants and although MutationTaster suggested that all intronic
and silent variants were likely tolerated, one BRCA1 (c.5242G>C) and two BRCA2 (c.9227G>
A and c.9227G>T) missense variants were classified as deleterious using all three predictors
(AlignGVGD, MutationTaster and PredictSNP).
Performance of different genetic testing criteria
Altogether, we evaluated 50 distinct criteria for genetic testing (all published in international
guidelines), in addition to the scores of commonly used pathogenic variant prediction tools
Table 1. (Continued)
All
participants
(N = 418)
Carriers of
pathogenic
variants
(N = 80)
Non-
carriers*
(N = 338)
P-value
N % N % N % Carriers vs Non-carriers
Male 60.5 (13.8) 64.0 (0.0) 59.8 (15.3)
Ovarian cancer 45.3 (13.9) 47.9 (8.7) 44.2 (15.8)
Other 47.4 (9.7) - 47.4 (9.7)
TNBC, triple-negative breast cancer; HR, hormonal receptor; IDC, invasive ductal carcinoma; DCIS, ductal
carcinoma in situ; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ.
* Non-carrier group is composed of WT individuals and VUS carriers.
(a) Birthplace data was missing for 45 individuals
(b) Other tumors are: endometrial cancer (1), colorectal cancer (1), renal clear cell carcinoma (1), thyroid
cancer (1), pancreatic cancer (2) and melanoma (2)
(c) Receptor status data was not available for 68 breast cancer patients
(d) Histology data was not available for 40 patients. In (c) and (d) only the status of the first tumor was
considered
(e) Patients diagnosed with both breast and ovarian cancer were excluded from this analysis
(f) Only the age at the first diagnosis was considered.
https://doi.org/10.1371/journal.pone.0187630.t001
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(PennII and Manchester models and Myriad Mutation Prevalence tables, using 10% as cutoff
point), for a total of 54 criteria (S1 Table). Among these, 25 criteria reached a statistically sig-
nificant odds-ratio of carrying a pathogenic variant (p 0.05) and the prevalence of patho-
genic variants varied significantly among these criteria, from 22.1% to 55.6%, as depicted in
Table 3. Criteria with the highest ORs were those related to triple-negative breast cancer or
ovarian cancer. Women with both breast and non-mucinous ovarian cancer have 5.4 times the
chance of carrying a pathogenic variant, compared to individuals without this phenotype.
Patients with both breast and ovarian primary tumors had a 54.5% chance of carrying a BRCA
pathogenic variant. It is noteworthy that 17.4% of all carriers with an early onset BC ( 45
years) had no family history of breast or ovarian cancer. Among early-onset BC patients with-
out bilateral and/or triple-negative tumor and without a family history of cancer (n = 31), the
prevalence of pathogenic variants was 6.5%. Also, two VUS carriers belong to this group.
ROC curve analyses performed with all 54 criteria demonstrated that the presence of ten or
more distinct criteria had 76.3% of sensitivity and 58.6% specificity (AUC 0.739; 95%CI 0.479–
Fig 2. Diagrams of the BRCA1 and BRCA2 genes, indicating the position of pathogenic variants identified among all 418 individuals
tested. Exons are indicated by blue boxes and numbered according to the Locus Reference Genomic (LRG) description. Different symbols
represent the type of variant, and each symbol indicates one germline carrier. Novel variants, described here for the first time are in bold. The ATG
sites and termination codons of both genes are indicated by arrows.
https://doi.org/10.1371/journal.pone.0187630.g002
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0.799) for harboring a pathogenic variant. Considering this cutoff, we found that an individual
above it has 4.8 times (95%CI 2.64–8.79) the chance of carrying a pathogenic BRCA variant,
compared to an individual who fulfills less than 10 of the criteria included here. Indeed,
among all individuals fulfilling 10 criteria, 28.9% carried a pathogenic variant, while those
individuals who fulfilled< 10 criteria had only a 7.8% chance of carrying a pathogenic variant.
We repeated this analysis considering only criteria with a statistically significant (p 0.05)
OR, and found that at a cutoff point of six or more criteria, the sensitivity and the specificity
for being a carrier of a pathogenic variant is 75% and 60.7%, respectively (AUC 0.773; 95%CI
0.717–0.830).
Fourteen clinical criteria had a highly statistical significant odds-ratio (p 0.001) for being
a carrier of a pathogenic variant. All carriers of pathogenic variants identified fulfilled at
least one of those criteria. In addition, the prevalence of pathogenic variants was directly
Table 2. Classification of the variants of uncertain significance (VUS) found in our cohort according to different databases and their effects as pre-
dicted by in silico models.
HGVS name Molecular consequence ClinVar dbSNP BRCAShare AlignGVGD MutationTaster PredictSNP
BRCA1
c.1258G>T (p.Asp420Tyr) Missense variant Conf. Int.a rs80357488 VUS C15 Polymorphism Deleterious
c.2763G>A (p.Gln921 =) Silent variant LB ND VUS NA Polymorphism NA
c.3868A>G (p.Lys1290Glu) Missense variant VUS rs80357254 ND C0 Disease causing Neutral
c.4724C>A (p.Pro1575His) Missense variant VUS rs80357052 VUS C0 Polymorphism Deleterious
c.5242G>C (p.Gly1748Arg) Missense variant VUS rs397507245 ND C65 Disease causing Deleterious
BRCA2
c.67+62T>G Intronic variant VUS rs11571574 ND NA Polymorphism NA
c.710A>G (p.Asp237Gly) Missense variant VUS rs730881506 ND C0 Polymorphism Neutral
c.1244A>G (p.His415Arg) Missense variant VUS rs80358417 VUS C0 Polymorphism Neutral
c.1680T>C (p.Asn560 =) Silent variant ND ND ND NA Polymorphism NA
c.2183A>C (p.Asp728Ala) Missense variant ND ND ND C0 Polymorphism Neutral
c.3321A>C (p.Gln1107His) Missense variant VUS rs397507306 ND C15 Disease causing Deleterious
c.4477G>C (p.Glu1493Gln)* Missense variant VUS rs398122782 ND C0 Polymorphism Deleterious
c.4627A>G (p.Lys1543Glu) Missense variant VUS rs786204239 ND C0 Polymorphism Neutral
c.6271A>G (p.Ser2091Gly) Missense variant ND ND ND C0 Polymorphism Neutral
c.6467C>T (p.Ser2156Phe) Missense variant VUS rs765575482 VUS C0 Polymorphism Deleterious
c.6988A>G (p.Ile2330Val) Missense variant VUS rs876661032 ND C0 Polymorphism Neutral
c.7006C>T (p.Arg2336Cys) Missense variant Conf. Int.b rs431825347 VUS C0 Polymorphism Neutral
c.7007+53G>A Intronic variant ND rs56014558 ND NA Polymorphism NA
c.9227G>A (p.Gly3076Glu) Missense variant Conf. Int.c rs80359187 ND C65 Disease causing Deleterious
c.9227G>T (p.Gly3076Val) Missense variant VUS rs80359187 ND C65 Disease causing Deleterious
c.10250A>G (p.Tyr3417Cys) Missense variant Conf. Int.d rs730881600 ND C0 Polymorphism Deleterious
c.9502-40T>A** Intronic variant ND rs563731281 ND NA Polymorphism NA
c.9502-45G>T** Intronic variant ND ND ND NA Polymorphism NA
ND, not described; NA, not applicable; LB, likely benign; Conf. Int, conflicting interpretations of pathogenicity in ClinVar:
(a) likely benign (2 submitters); VUS (2 submitters)
(b) likely benign (1 submitter); VUS (3 submitters)
(c) likely pathogenic (1 submitter); VUS (4 submitters)
(d) likely benign (1 submitter); VUS (1 submitter). Variants for which all three in silico tools predicted a deleterious effect are shown are in bold.
(*) the variant c.4477G>C was found in two individuals.
(**) both variants were found in the same individual. AlignGVGD classifies each variant from C65 (most likely to interfere with function) to C0 (least likely).
https://doi.org/10.1371/journal.pone.0187630.t002
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proportional to the number of these 14 criteria that were fulfilled (S1 Fig). Considering only
these 14 criteria, ROC curve analysis showed that at a cutoff point of four or more criteria, the
sensitivity is 83.8%, and the specificity is 53.5% (AUC 0.776; p 0.001) for being a carrier of a
pathogenic variant. The chance of carrying a pathogenic variant among probands fulfilling
4 of the 14 criteria is 5.8 times the chance of an individual with less than four of these criteria
(p 0.001, 95%CI 3.12–11.03). The ROC curves of all three criteria sets are depicted in Fig 3.
Table 3. Performance of testing criteria with significant odds ratios.
Criteria
#
Testing criteria Reference Prevalence of pathogenic
variants(%)*
OR 95% CI P
52 Familial PennII Score10 18 22.1 7.643 1.822–32.062 <0.001
39 Family with sister pair with BC and OC, both
diagnosed < 50y
9 55.6 5.567 1.460–21.226 0.015
53 Myriad Table Score 10 19 35.9 5.553 3.262–9.455 <0.001
44 Family with 2 BC and/or OC, and at least 1 OC 14 49.1 5.546 3.010–10.219 <0.001
11 Personal history of BC and non-mucinous OC 15 54.5 5.400 1.605–18.168 0.008
35 Family with2 BC and1 OC at any age 9 48.9 5.195 2.717–9.932 <0.001
10 Personal history of triple negative BC diagnosed60 y 10, 11, 12, 13,
16
44.2 5.014 2.871–8.756 <0.001
9 Personal history of triple negative BC 15 43.6 4.881 2.8–8.509 <0.001
23 Personal history of BC at any age and1 close relative
with OC
11, 13, 16 46.2 4.382 2.207–8.701 <0.001
13 Personal history of non-mucinous OC 15 46.7 4.229 1.482–12.067 0.01
54 Manchester Score 10 17 22.5 4.014 1.685–9.563 <0.001
36 Family with3 BC diagnosed < 50 y 9 40.0 3.595 1.993–6.486 <0.001
50 Personal history of BC and relatives with cancer and
Manchester Score15
15 31.1 3.502 2.105–5.824 <0.001
51 Individual PennII Score 10 18 22.6 3.345 1.479–7.564 0.002
40 Family history of OC (non-mucinous) 12 38.3 3.282 1.815–5.936 <0.001
42 Family with3 BC and/or OC 14 28.4 2.935 1.764–4.881 <0.001
12 Personal history of epithelial OC 10, 11, 12, 13,
16
37.8 2.905 1.421–5.941 0.007
46 Family with 2 BC: one bilateral and the other diagnosed < 50
y
14 37.1 2.787 1.337–5.810 0.011
37 Family with sister pair with BC, both diagnosed < 50y 9 34.5 2.613 1.405–4.858 0.003
6 Personal history of bilateral BC, both diagnosed < 60 y 15 35.5 2.535 1.161–5.532 0.029
45 Family with 2 BC diagnosed < 50 y 14 28.7 2.509 1.528–4.119 <0.001
21 Personal history of BC at any age and1 close relative
with BC diagnosed50 y
11, 13, 16 27.4 2.395 1.459–3.933 0.001
19 Personal history of BC and a relative with BC, both
diagnosed < 50y
15 29.9 2.258 1.332–3.827 0.003
22 Personal history of BC at any age and2 close relative with
BC at any age
11, 13, 16 27.3 2.123 1.292–3.489 0.004
8 Personal history of BC diagnosed50 y and a limited family
historya
11, 13, 16 28.0 1.908 1.090–3.340 0.028
The fourteen most significant criteria are in bold (P 0.001). BC, breast cancer; y, years; OC, ovarian cancer
*Percentage of individuals fulfilling the criteria and carrying a pathogenic variant.
(a) “Unknown” or “limited family history” applies to individuals with a unknown history or a family with fewer than two first- or second-degree female relatives
living beyond age 45.
https://doi.org/10.1371/journal.pone.0187630.t003
BRCA1 and BRCA2 mutational profile and testing criteria in Southern Brazil
PLOS ONE | https://doi.org/10.1371/journal.pone.0187630 November 21, 2017 11 / 18
It is well known that in a context of low resources there may be a lack of clinically relevant
data, as hormone receptor and HER2 status, as well as a detailed family history. Considering
this scenario, a ROC curve was used to evaluate the sensitivity of a set of criteria relying only
on proband diagnosis, age of onset and limited family history. Using a total of 11 distinct crite-
ria, we show that these criteria were not good predictors of being a carrier of pathogenic vari-
ant (AUC 0.580; 95%CI 0.509–0.652, data not shown). Indeed, at a cutoff point of two or more
Fig 3. Performance of three distinct criteria sets. Considering all criteria (N = 54, dashed blue line); considering only criteria with p 0.05 in the OR
analysis (N = 25, dashed green line); and considering only criteria with p 0.001 in the same analysis (N = 14, solid purple line).
https://doi.org/10.1371/journal.pone.0187630.g003
BRCA1 and BRCA2 mutational profile and testing criteria in Southern Brazil
PLOS ONE | https://doi.org/10.1371/journal.pone.0187630 November 21, 2017 12 / 18
criteria, the sensitivity and specificity of being a carrier of a pathogenic variant are 66.3%
41.4%, respectively.
Discussion
The identification of a carrier of a pathogenic variant in BRCA1 or BRCA2 can significantly
impact their medical management, as well as that of at-risk family members, since several can-
cer risk-reducing strategies are available. In addition, true negative results from cascade testing
for relatives of a known carrier provides reassurance and allows application of general popula-
tion screening guidelines, thereby avoiding unnecessary and costly screening tests and reduc-
ing anxiety related to cancer risk. The majority of at-risk individuals in Brazil (the ~70% of the
population that relies on the public health care system) do not have access to genetic testing.
Thus, national as well as regional molecular profiles of families with the HBOC phenotype
have remained largely unknown. Although studies involving Brazilian subjects have been pub-
lished, most did not include sequencing of the entire coding region and rearrangement testing
of both BRCA1 and BRCA2 [13, 31]. In addition, many are focused on a specific population
and/or involve small cohorts [7–10]. To the best of our knowledge, this is the largest Brazilian
study with comprehensive BRCA testing to date. It is also the first to evaluate the performance
of international testing criteria in this Southern Brazilian population.
In agreement with other studies [32], our data suggests that age at diagnosis (especially
for breast cancer), bilateral and/or triple-negative disease, and a diagnosis of ovarian cancer
are the findings with the highest predictive value for a testing result positive for a pathogenic
variant. Interestingly, in our cohort, epithelial ovarian cancer was diagnosed at a later age in
carriers when compared to non-carriers (not statistically significant). A recent study from
Azzollini et al [11] highlighted the impact of ovarian cancer cases on the detection rates of
pathogenic variants, reporting a mutational prevalence up to 56% among breast and ovarian
cancer families. Moreover, breast and ovarian or early-onset ovarian cancer probands with
negative family history showed remarkably high detection rates, 43.3% and 26.7%, respectively.
Taken together, these findings underscore the importance of testing ovarian cancer patients of
all ages, regardless the family history.
The prevalence of pathogenic variants in our cohort was similar to that described in other
studies, both in Brazil and in other countries, especially when considering only cancer-affected
individuals (prevalence of 20%) [7–10] (Table 4). In addition, also in accordance with other
studies from Brazil [7–10] and many other European countries [33], the BRCA1 c.5266dupC
(formerly known as 5382insC) was the most prevalent pathogenic variant, corresponding to
17.6% of all pathogenic variants in BRCA1.
The overall expected frequency of VUS among BRCA tested individuals worldwide is about
7%, but this frequency may vary depending on the patient’s ethnicity, increasing up to 21% in
Table 4. Prevalence of BRCA pathogenic variants in Brazilian studies performing comprehensive analysis of BRCA1 and BRCA2 among HBOC
cohorts.
Reference Sample size Inclusion criteria BRCA mutation prevalence
Carraro et al., 2013 54 BC diagnosed < 35 y* 20.4%
Silva et al., 2014 120 HBOC criteria 22.5%
Fernandes et al., 2016 349 HBOC criteria 21.5%
Maistro et al., 2016 100 Epithelial OC* 19.0%
Alemar et al., 2017 (present study) 418 HBOC criteria 19.1%
*These criteria are also considered “HBOC criteria” according to the NCCN v.2014.2.
https://doi.org/10.1371/journal.pone.0187630.t004
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African-Americans [34]. Not surprisingly, considering the predominance of European ances-
try in Southern Brazil, VUS were identified in 5.7% of our patients, similar to the prevalence
described in North-Americans of European descent (5–6%) [34].
Surprisingly, our rate of novel pathogenic variants (12.5%) identified was lower than previ-
ously described in other Brazilian regions: 25% in the cohort reported by Silva et al [8] and
30% in the study of Carraro et al [7]. This again could be due to the higher proportion of Euro-
peans in the population in Southern Brazil, with lower proportions of African- and Amerin-
dian-ancestry than in other Brazilian regions. The lower rate of novel pathogenic variants
could be due to the fact that most of the patients studied today worldwide are of European
countries or of European descent. Another noteworthy finding from our study is the high
prevalence of double heterozygous mutant individuals. In previous large cohorts of Brazilian
patients, none of the patients studied was a carrier of more than one germline pathogenic vari-
ant in a BRCA gene. Double BRCA1 and BRCA2 heterozygotes have been described in only a
few studies and have been considered rare in most populations [35]. Therefore it is surprising
that in our population 2.5% of all carriers were double heterozygotes, if we include one patient
carrying two BRCA2 pathogenic variants. However, because the patient did not present with a
phenotype of Fanconi’s Anemia these variants are likely to be in the same BRCA2 allele (i.e. in
cis). The parents were not available for testing, to confirm this hypothesis.
One of the most important determinants of the yield of genetic testing is the testing criteria
used. The fact that our overall prevalence of pathogenic variants was similar to that described
in other countries indicates that the NCCN criteria, used for patient selection in our study, are
performing well in the identification of carriers of pathogenic variants in this group of patients.
However, we showed that several criteria not included in the NCCN or in the Brazilian (ANS)
testing guidelines (e.g. ASCO criteria, criteria #35—Family with2 BC and1 OC at any
age, #36—Family with3 BC diagnosed < 50 y, #37—Family with sister pair with BC, both
diagnosed < 50y and #39—Family with sister pair with BC and OC, both diagnosed < 50y,
Table 3) had very high odds ratios for carrying a pathogenic variant. This is not unexpected,
since these criteria are far more stringent than the NCCN criteria, and suggests that those cri-
teria could be used as a prioritization approach in this population, in a scenario of limited
resources. In addition, we observed that individuals fulfilling multiple criteria are more likely
to carry a BRCA pathogenic variant. Also, the comparison between the predictive performance
of distinct criteria sets (Fig 3) shown that the use of a large set of criteria did not improve the
performance. In contrast, the use of a smaller set of criteria (N = 14) with high p-values in the
OR analysis (p 0.001) shown better results (AUC 0.776, 95%CI 0.720–0.833). The identifica-
tion of highly predictive criteria in a specific population could guide establishment of priorities
in genetic testing in a scenario of limited resources. Although this is the largest HBOC cohort
published in Brazil it is relatively small and local. For this reason, we do not intend to make a
formal recommendation, but instead our data aim to raise awareness and discuss the possibil-
ity of change the criteria used to decide who should be tested in a specific context of limited
resources.
Several limitations must be considered when analyzing the data presented here. First, the
cohort of patients studied, although significant in size is probably not entirely representative of
the population of Southern Brazil. Brazil is a country of continental dimensions and formed by
a very admixed population with contributions from Europeans, Africans and Native Ameri-
cans in different proportions according to geographic region [36]. Thus, it is possible that the
profile of pathogenic variants will be unique in different Brazilian regions. Also, besides
patients prospectively recruited, this study also included retrospective data. Moreover, since
we recruited patients from high risk clinics, the performance of selected criteria may not be
the same for individuals in the general population. Although all participants fulfilled the same
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clinical criteria (NCCN version 2014.2), they were recruited from different clinics and a het-
erogeneity in variant testing strategies was present, with some individuals being tested by
Sanger sequencing and others by NGS. In addition, LGR analysis was incomplete, mainly due
to the fact that until very recently testing in Brazil followed a stepwise approach with sequenc-
ing being done first. The lack of LGR analysis in some individuals, as well as the absence of
specific testing for the Portuguese founder rearrangement, BRCA2 c.156_157insAlu, may have
underestimated its frequency and could also have impacted the frequency of double heterozy-
gotes. Our LGR prevalence (1.19%), however, is not significantly different from that reported
in previous comprehensive Brazilian studies (0.29% [9], 1.7% [8] and 2% [10]), indicating that
an underestimation is not likely. Gleason scores were not available for most prostate cancer
cases and not all cancers in the proband’s relatives could be confirmed by pathology and medi-
cal reports. Finally, the small number of probands fulfilling some of the criteria could have had
an impact on the robustness of the respective ORs.
In conclusion, this is the first comprehensive study on the molecular profile of HBOC pro-
bands from Southern Brazil. The prevalence of pathogenic variants is similar to that observed in
other Brazilian studies and in other countries, and BRCA1 and BRCA2 molecular heterogeneity
is also as striking as described in most populations. The identification of a significant proportion
of double heterozygotes in our cohort reinforces the importance of comprehensive BRCA gene
testing. Finally, with this study we have demonstrated that a specific subset of clinical criteria
are highly predictive of carrying a pathogenic variant in this population. Taken together with
the significantly reduced sequencing costs of next generation sequencing, the strategy of identi-
fying criteria which are highly predictive for presence of a pathogenic variant in a specific popu-
lation could be used as a first step to prioritize genetic testing in a scenario of limited resources.
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